Free Trial
NASDAQ:SMTI

Sanara MedTech (SMTI) Stock Price, News & Analysis

Sanara MedTech logo
$33.51
+0.51 (+1.55%)
(As of 11/1/2024 ET)

About Sanara MedTech Stock (NASDAQ:SMTI)

Key Stats

Today's Range
$32.00
$33.63
50-Day Range
$29.00
$35.89
52-Week Range
$26.00
$43.25
Volume
15,305 shs
Average Volume
25,564 shs
Market Capitalization
$293.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00
Consensus Rating
Buy

Company Overview

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Sanara MedTech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
42nd Percentile Overall Score

SMTI MarketRank™: 

Sanara MedTech scored higher than 42% of companies evaluated by MarketBeat, and ranked 799th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sanara MedTech has received no research coverage in the past 90 days.

  • Read more about Sanara MedTech's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sanara MedTech is -42.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sanara MedTech is -42.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sanara MedTech has a P/B Ratio of 6.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Sanara MedTech's valuation and earnings.
  • Percentage of Shares Shorted

    6.13% of the float of Sanara MedTech has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanara MedTech has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Sanara MedTech has recently decreased by 4.41%, indicating that investor sentiment is improving.
  • Dividend Yield

    Sanara MedTech does not currently pay a dividend.

  • Dividend Growth

    Sanara MedTech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.13% of the float of Sanara MedTech has been sold short.
  • Short Interest Ratio / Days to Cover

    Sanara MedTech has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Sanara MedTech has recently decreased by 4.41%, indicating that investor sentiment is improving.
  • News Sentiment

    Sanara MedTech has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Sanara MedTech this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for SMTI on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sanara MedTech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    54.10% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 8.10% of the stock of Sanara MedTech is held by institutions.

  • Read more about Sanara MedTech's insider trading history.
Receive SMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.

SMTI Stock News Headlines

Sanara MedTech (NASDAQ:SMTI) Trading Up 1.5% - Here's What Happened
Urgent: This election is rigged
If you missed it, my emergency election broadcast is now available - but will be removed soon
InfuSystem Holdings, Inc. (1TZ.F)
See More Headlines

SMTI Stock Analysis - Frequently Asked Questions

Sanara MedTech's stock was trading at $41.10 at the start of the year. Since then, SMTI shares have decreased by 18.5% and is now trading at $33.51.
View the best growth stocks for 2024 here
.

Sanara MedTech Inc. (NASDAQ:SMTI) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.41) earnings per share (EPS) for the quarter. The firm earned $20.16 million during the quarter. Sanara MedTech had a negative net margin of 9.07% and a negative trailing twelve-month return on equity of 15.17%.

Sanara MedTech's top institutional shareholders include Janney Montgomery Scott LLC (0.38%). Insiders that own company stock include Zachary B Fleming and Shawn M Bowman.
View institutional ownership trends
.

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/12/2024
Today
11/01/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:SMTI
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.00
High Stock Price Target
$44.00
Low Stock Price Target
$44.00
Potential Upside/Downside
+31.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,300,000.00
Pretax Margin
-9.23%

Debt

Sales & Book Value

Annual Sales
$64.99 million
Book Value
$5.22 per share

Miscellaneous

Free Float
4,015,000
Market Cap
$293.21 million
Optionable
Not Optionable
Beta
1.58
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:SMTI) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners